T. Frenkl

发表

Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).

T. Powles, E. Plimack, D. Bajorin, 2018 .

Male urinary incontinence.

T. Frenkl, Young Ho Kim, Young H. Kim, 2002, Medicine and health, Rhode Island.

Vibegron (RVT-901/MK-4618/KRP-114V) Administered Once Daily as Monotherapy or Concomitantly with Tolterodine in Patients with an Overactive Bladder: A Multicenter, Phase IIb, Randomized, Double-blind, Controlled Trial.

S. Green, C. Pinto, P. Mudd, 2019, European urology.

Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status

T. Powles, E. Plimack, D. Bajorin, 2020, European urology oncology.

KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC.

H. Nishiyama, S. Shariat, G. Steinberg, 2020, Future oncology.

Phase II dose-finding study on ovulation inhibition and cycle control associated with the use of contraceptive vaginal rings containing 17β-estradiol and the progestagens etonogestrel or nomegestrol acetate compared to NuvaRing

T. Frenkl, D. Heger-Mahn, C. Klipping, 2018, The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception.

Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study.

D. Bajorin, H. Nishiyama, A. Balar, 2021, The Lancet. Oncology.

The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States

G. Sonpavde, T. Frenkl, B. Homet Moreno, 2020, Journal of medical economics.

Results of cystocele repair: a comparison of traditional anterior colporrhaphy, polypropylene mesh and porcine dermis.

T. Frenkl, Y. H. Kim, Liann N. Handel, 2006, The Journal of urology.

Discovery of Vibegron: A Potent and Selective β3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder.

M. Struthers, R. Berger, C. Moyes, 2016, Journal of medicinal chemistry.

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

S. Culine, M. Climent, T. Choueiri, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicenter, double-blind, randomized, placebo controlled trial of a neurokinin-1 receptor antagonist for overactive bladder.

S. Green, T. Reiss, Haiyuan Zhu, 2010, The Journal of urology.

Evaluation of an experimental urodynamic platform to identify treatment effects: A randomized, placebo‐controlled, crossover study in patients with overactive bladder

R. Railkar, C. Beals, T. Frenkl, 2012, Neurourology and urodynamics.

Sexually transmitted infections.

J. Potts, T. Frenkl, 2008, The Urologic clinics of North America.

Injectable neuromodulatory agents: botulinum toxin therapy.

T. Frenkl, R. Rackley, 2005, The Urologic clinics of North America.

Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III study

D. Papanicolaou, H. Kehlet, P. Peloso, 2012, Current medical research and opinion.

Results of a simplified technique for buried penis repair.

T. Frenkl, A. Caldamone, S. Agarwal, 2004, The Journal of urology.

Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer.

T. Powles, E. Plimack, D. Bajorin, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial

D. Bajorin, H. Nishiyama, J. Bellmunt, 2019, International Journal of Clinical Oncology.

Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).

D. Bajorin, H. Nishiyama, A. Balar, 2019, Journal of Clinical Oncology.

Management of iatrogenic foreign bodies of the bladder and urethra following pelvic floor surgery

H. Goldman, T. Frenkl, R. Rackley, 2008, Neurourology and urodynamics.

Sacral Neuromodulation Therapy

T. Frenkl, R. Rackley, 2007 .

Pelvic hematoma as a cause of bladder perforation and gross hematuria.

M. Moy, B. Lane, F. Daneshgari, 2004, Urology.

Safety and efficacy of the NuvaRing® Applicator in healthy females: a multicenter, open-label, randomized, 2-period crossover study.

T. Frenkl, Yinna Wang, R. Feldman, 2016, Contraception.

KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)— Updated response and survival results.

T. Powles, E. Plimack, D. Bajorin, 2019, Journal of Clinical Oncology.

Office based transurethral needle ablation of the prostate with analgesia and local anesthesia.

T. Frenkl, B. Stein, D. Leocádio, 2007, The Journal of urology.

Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder

M. Struthers, J. Demartino, J. Woods, 2017, The Journal of Pharmacology and Experimental Therapeutics.

Conservative Management of Urinary Retention in Women

F. Daneshgari, T. Frenkl, 2006 .

Two-year follow-up from the phase 3 KEYNOTE-045 trial of pembrolizumab (pembro) vs investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC).

S. Culine, M. Climent, T. Choueiri, 2018 .

Systematic Literature Review and Meta-Analysis of Response to First-Line Therapies for Advanced/Metastatic Urothelial Cancer Patients Who Are Cisplatin Ineligible

R. Perini, T. Frenkl, S. Keefe, 2019, American Journal of Clinical Oncology.

Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction.

H. Nishiyama, S. Shariat, G. Steinberg, 2019, Journal of Clinical Oncology.

Pembrolizumab for high-risk (HR) non-muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG): Phase II KEYNOTE-057 trial.

D. Bajorin, A. Balar, A. Kamat, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Understanding Mid For Micturition Frequency, A Pivotal Endpoint For Oab Studies

C. Pinto, C. Girman, T. Frenkl, 2014 .

Bladder dysfunction in mice with experimental autoimmune encephalomyelitis

V. Tuohy, F. Daneshgari, Guiming Liu, 2008, Journal of Neuroimmunology.

Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057.

D. Bajorin, H. Nishiyama, A. Balar, 2019, Journal of Clinical Oncology.

857PPembrolizumab (pembro) as first-line therapy in cisplatin-ineligible advanced urothelial cancer (UC): Outcomes from KEYNOTE-052 in senior patients (pts) with poor performance status

T. Powles, E. Plimack, D. Bajorin, 2017 .

Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC)

S. Culine, M. Climent, T. Choueiri, 2019, Annals of Oncology.

Pembrolizumab (pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC): 2-year follow-up from the phase 3 KEYNOTE-045 trial.

S. Culine, M. Climent, T. Choueiri, 2018 .

Tissue distribution and brain penetration of niraparib in tumor bearing mouse models and its clinical relevance.

G. Fulci, E. Minthorn, D. Lugo, 2021 .